Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
The University of Hong Kong
Fresienius Kabi HK Ltd
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00563498
First received: November 21, 2007
Last updated: July 6, 2010
Last verified: July 2010

November 21, 2007
July 6, 2010
July 2004
Not Provided
  • Veno-occlusive disease [ Time Frame: 1 month ]
  • Mucositis [ Time Frame: 1 month ]
Same as current
Complete list of historical versions of study NCT00563498 on ClinicalTrials.gov Archive Site
  • Hospital stay [ Time Frame: 2 months ]
  • Use of antibiotics [ Time Frame: 2 months ]
Same as current
Not Provided
Not Provided
 
Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients
A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.

The primary purpose of this project is to investigate if addition of glutamine, an amino acid, to standard parenteral nutrition, may improve the clinical outcome of the bone marrrow transplantation reducing the occurrence of veno-occlusive disease and severity of mucositis.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
  • Pulmonary Veno-Occlusive Disease
  • Hepatic Veno-Occlusive Disease
  • Mucositis
Drug: Glutamine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
June 2006
Not Provided

Inclusion Criteria:

  • Allogeneic bone marrow transplant recipients using busulfan and cyclophosphamide as conditioning.
Both
18 Years and older
Not Provided
Contact: YH Leung, Dr (852) 2855 3347 ayhleung@hku.hk
China
 
NCT00563498
EC1432-00, HARECCTR0500034
Not Provided
Not Provided
Hospital Authority, Hong Kong
  • The University of Hong Kong
  • Fresienius Kabi HK Ltd
Principal Investigator: Albert Lie, Dr Department of Medicine/Division of Haematology, Queen Mary Hospital/ The University of Hong Kong
Hospital Authority, Hong Kong
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP